Avadel Pharmaceuticals PLC
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.68
- Today's High:
- $13.175
- Open Price:
- $12.92
- 52W Low:
- $2.12
- 52W High:
- $15.82
- Prev. Close:
- $12.89
- Volume:
- 363443
Company Statistics
- Market Cap.:
- $1.13 billion
- Book Value:
- -0.592
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $16.59 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -32.78%
- Return on Equity TTM:
- -1662.07%
Company Profile
Avadel Pharmaceuticals PLC had its IPO on 1996-06-07 under the ticker symbol AVDL.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Avadel Pharmaceuticals PLC has a staff strength of 41 employees.
Stock update
Shares of Avadel Pharmaceuticals PLC opened at $12.92 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.68 - $13.18, and closed at $12.7.
This is a -1.47% slip from the previous day's closing price.
A total volume of 363,443 shares were traded at the close of the day’s session.
In the last one week, shares of Avadel Pharmaceuticals PLC have slipped by -5.08%.
Avadel Pharmaceuticals PLC's Key Ratios
Avadel Pharmaceuticals PLC has a market cap of $1.13 billion, indicating a price to book ratio of 7.6327 and a price to sales ratio of 44.8284.
In the last 12-months Avadel Pharmaceuticals PLC’s revenue was $0 with a gross profit of $16.59 million and an EBITDA of $-93066000. The EBITDA ratio measures Avadel Pharmaceuticals PLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Avadel Pharmaceuticals PLC’s operating margin was 0% while its return on assets stood at -32.78% with a return of equity of -1662.07%.
In Q1, Avadel Pharmaceuticals PLC’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Avadel Pharmaceuticals PLC’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0.07
Its diluted EPS in the last 12-months stands at $-2.39 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.07. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Avadel Pharmaceuticals PLC’s profitability.
Avadel Pharmaceuticals PLC stock is trading at a EV to sales ratio of 38.1481 and a EV to EBITDA ratio of -4.7341. Its price to sales ratio in the trailing 12-months stood at 44.8284.
Avadel Pharmaceuticals PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $140.74 million
- Total Liabilities
- $79.36 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Avadel Pharmaceuticals PLC ended 2024 with $140.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $140.74 million while shareholder equity stood at $-38166000.00.
Avadel Pharmaceuticals PLC ended 2024 with $0 in deferred long-term liabilities, $79.36 million in other current liabilities, 644000.00 in common stock, $-616004000.00 in retained earnings and $16.84 million in goodwill. Its cash balance stood at $83.39 million and cash and short-term investments were $100.92 million. The company’s total short-term debt was $21,386,000 while long-term debt stood at $93.14 million.
Avadel Pharmaceuticals PLC’s total current assets stands at $109.47 million while long-term investments were $0 and short-term investments were $17.53 million. Its net receivables were $2.28 million compared to accounts payable of $10.02 million and inventory worth $0.
In 2024, Avadel Pharmaceuticals PLC's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Avadel Pharmaceuticals PLC paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $12.7
- 52-Week High
- $15.82
- 52-Week Low
- $2.12
- Analyst Target Price
- $16.85
Avadel Pharmaceuticals PLC stock is currently trading at $12.7 per share. It touched a 52-week high of $15.82 and a 52-week low of $15.82. Analysts tracking the stock have a 12-month average target price of $16.85.
Its 50-day moving average was $13.93 and 200-day moving average was $11.07 The short ratio stood at 2.73 indicating a short percent outstanding of 0%.
Around 521.5% of the company’s stock are held by insiders while 4516.7% are held by institutions.
Frequently Asked Questions About Avadel Pharmaceuticals PLC
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.